DrugPatentWatch Database Preview
Details for New Drug Application (NDA): 021253
Email this page to a colleague
» See Plans and Pricing
NDA 021253 describes ZYPREXA, which is a drug marketed by Lilly and Eli Lilly Co and is included in four NDAs. It is available from one supplier. Additional details are available on the ZYPREXA profile page.
The generic ingredient in ZYPREXA is olanzapine pamoate. There are thirty-three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the olanzapine pamoate profile page.
The generic ingredient in ZYPREXA is olanzapine pamoate. There are thirty-three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the olanzapine pamoate profile page.
Summary for 021253
| Tradename: | ZYPREXA |
| Applicant: | Lilly |
| Ingredient: | olanzapine |
| Patents: | 0 |
| Formulation / Manufacturing: | see details |
Suppliers and Packaging for NDA: 021253
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| ZYPREXA | olanzapine | INJECTABLE;INTRAMUSCULAR | 021253 | NDA | Eli Lilly and Company | 0002-7597 | 0002-7597-01 | 1 VIAL in 1 CARTON (0002-7597-01) > 2 mL in 1 VIAL |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | INJECTABLE;INTRAMUSCULAR | Strength | 10MG/VIAL | ||||
| Approval Date: | Mar 29, 2004 | TE: | AP | RLD: | Yes | ||||
Expired US Patents for NDA 021253
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Lilly | ZYPREXA | olanzapine | INJECTABLE;INTRAMUSCULAR | 021253-001 | Mar 29, 2004 | Start Trial | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription
